Evidence map›Paper›PMID 33052054›Full record

ArticleArteriosclerosis, thrombosis, and vascular biology2020

Platelets Promote Thromboinflammation in SARS-CoV-2 Pneumonia.

Francesco Taus, Gianluca Salvagno, Stefania Canè, Cristiano Fava, Fulvia Mazzaferri, Elena Carrara, Varvara Petrova, Roza Maria Barouni, Francesco Dima, Andrea Dalbeni and 10 more

Registry-linked trialOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Arteriosclerosis, thrombosis, and vascular biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04808895 (Multicenter Randomized, Double-blind, Placebo-controlled, Clinical Trial of Acetylsalicylic Acid in the Prevention of Severe SARS-CoV2 Pneumonia in Hospitalised Patients), which is not on this map. Cited by 112 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
112citing papers in PubMed, 7 pooled it
3.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04808895 phase3unknown statusnot on this mapstarted 2021, after this paper: background citation

Multicenter Randomized, Double-blind, Placebo-controlled, Clinical Trial of Acetylsalicylic Acid in the Prevention of Severe SARS-CoV2 Pneumonia in Hospitalised Patients (Asperum)

TypeinterventionalSponsorAzienda Ospedaliera Universitaria Integrata VeronaRan2021 to 2021Enrolled204ConditionsCOVID-19, Thrombosis PulmonaryArmsAcetylsalicylic acid, Placebo
3 · Its place in the literature

Who cites it

112 citing papers in PubMed, 7 syntheses or guidelines pooled it, 172 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. [Pulmonary innate immune response in Sars-cov-2 infection]Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina) · 2022
    Pooled it
  5. Pooled it
  6. Pooled it
  7. The Role of P-Selectin in COVID-19 Coagulopathy: An Updated Review.International journal of molecular sciences · 2021
    Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Review
  13. Article
  14. Article
  15. Beyond hemostasis, the immunomodulatory nature of platelets.Research and practice in thrombosis and haemostasis · 2025
    Review
  16. Article
  17. Article
  18. Article
  19. COVID-19: a vascular nightmare unfolding.Frontiers in immunology · 2025
    Review
  20. Article

52 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 3 countries.

Francesco Taus *Department of Medicine, Section of General Medicine and Hypertension (T.F., F.C., D.A., R.S., M.P.), University of Verona, Italy.
Gianluca Salvagno *Laboratory of Clinical Biochemistry, Department of Life and Reproduction Sciences (S.G., D.F., P.G., B.M., D.S., L.G.), University of Verona, Italy.
Stefania Canè *Immunology Section, Department of Medicine, University and Hospital Trust of Verona, Italy (C.S., P.V., B.R.M., B.V.).
Cristiano FavaDepartment of Medicine, Section of General Medicine and Hypertension (T.F., F.C., D.A., R.S., M.P.), University of Verona, Italy.
Fulvia MazzaferriDepartment of Diagnostics and Public Health, Section of Infectious Diseases (M.F., C.E., T.E.), University of Verona, Italy.
Elena CarraraDepartment of Diagnostics and Public Health, Section of Infectious Diseases (M.F., C.E., T.E.), University of Verona, Italy.
Varvara PetrovaImmunology Section, Department of Medicine, University and Hospital Trust of Verona, Italy (C.S., P.V., B.R.M., B.V.).
Roza Maria BarouniImmunology Section, Department of Medicine, University and Hospital Trust of Verona, Italy (C.S., P.V., B.R.M., B.V.).
Francesco DimaLaboratory of Clinical Biochemistry, Department of Life and Reproduction Sciences (S.G., D.F., P.G., B.M., D.S., L.G.), University of Verona, Italy.
Andrea DalbeniDepartment of Medicine, Section of General Medicine and Hypertension (T.F., F.C., D.A., R.S., M.P.), University of Verona, Italy.
Simone RomanoDepartment of Medicine, Section of General Medicine and Hypertension (T.F., F.C., D.A., R.S., M.P.), University of Verona, Italy.
Giovanni PoliLaboratory of Clinical Biochemistry, Department of Life and Reproduction Sciences (S.G., D.F., P.G., B.M., D.S., L.G.), University of Verona, Italy.
Marco BenatiLaboratory of Clinical Biochemistry, Department of Life and Reproduction Sciences (S.G., D.F., P.G., B.M., D.S., L.G.), University of Verona, Italy.
Simone De Nitto
Giancarlo MansuetoDepartment of Diagnostic and Public Health, Section of Radiology (M.G.), University of Verona, Italy.
Manuela IezziCenter for Advanced Studies and Technology, University G. D'Annunzio of Chieti-Pescara, Italy (I.M.).
Evelina TacconelliDepartment of Diagnostics and Public Health, Section of Infectious Diseases (M.F., C.E., T.E.), University of Verona, Italy.
Giuseppe LippiLaboratory of Clinical Biochemistry, Department of Life and Reproduction Sciences (S.G., D.F., P.G., B.M., D.S., L.G.), University of Verona, Italy.
Vincenzo BronteImmunology Section, Department of Medicine, University and Hospital Trust of Verona, Italy (C.S., P.V., B.R.M., B.V.).
Pietro MinuzDepartment of Medicine, Section of General Medicine and Hypertension (T.F., F.C., D.A., R.S., M.P.), University of Verona, Italy.
University of Verona · ITUniversity Hospital Foundation · CANitto (United States) · USSanta Maria Nuova Hospital · ITUniversity of Chieti-Pescara · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivePulmonary thrombosis is observed in severe acute respiratory syndrome coronavirus 2 pneumonia. Aim was to investigate whether subpopulations of platelets were programmed to procoagulant and inflammatory activities in coronavirus disease 2019 (COVID-19) patients with pneumonia, without comorbidities predisposing to thromboembolism. Approach and Results: Overall, 37 patients and 28 healthy subjects were studied. Platelet-leukocyte aggregates, platelet-derived microvesicles, the expression of P-selectin, and active fibrinogen receptor on platelets were quantified by flow cytometry. The profile of 45 cytokines, chemokines, and growth factors released by platelets was defined by immunoassay. The contribution of platelets to coagulation factor activity was selectively measured. Numerous platelet-monocyte (mean±SE, 67.9±4.9%, n=17 versus 19.4±3.0%, n=22;

conclusionsPlatelets in COVID-19 pneumonia are primed to spread proinflammatory and procoagulant activities in systemic circulation.

Indexed as

AgedAged, 80 and overBlood PlateletsCOVID-19CytokinesFemaleFlow CytometryHumansMaleMiddle AgedPandemicsPrognosisThromboembolismCytokinesblood plateletsinflammationinterferonsmonocytesthrombosis

Identifiers

PMID33052054
PMCPMC7682791
OpenAlexW3092237271

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.